- Oops!Something went wrong.Please try again later.
Assays expected to be capable of broad-based fecal pathogen identification in minutes for diagnosing infections in dogs and cats - complementary to Zomedica’s development work related to urine pathogens
ANN ARBOR, Mich., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM)(“Zomedica” or “Company”), a veterinary diagnostic company, announced today that the Company has filed a U.S. patent application covering compositions and methods for five fecal parasite detection assays for detecting parasitic infections in cats and dogs designed for use with its ZM-020 pathogen detection device. The patent application details optimal fecal sample amounts for parasite infection detection. In early 2019 Zomedica previously submitted a U.S. provisional patent application covering compositions and methods for detecting urinary tract infections (UTIs) designed for use with its ZM-020 pathogen detection platform to detect urinary tract infections in dogs and cats. The initial library of pathogens for urine samples is focused on the identification of Escherichia coli, Staphylococcus, Streptococcus, Klebsiella, Pseudomonas bacteria species and three types of crystals and white blood cells. The initial library of pathogens for fecal samples is focused on the identification of hookworms, roundworms, whipworms, coccidia and giardia.
The assays are intended to be used with the ZM-020 pathogen detection device which is a miniaturized Raman spectroscopy platform capable of broad-based pathogen identification in minutes. The technology used in the ZM-020 device, which is currently being developed by Seraph Biosciences, Inc. (“Seraph”) has the potential to achieve reference lab sensitivity/specificity in-clinic during the point-of-care experience, which could result in better pet outcomes and faster recovery. The ZM-020 diagnostic platform requires a small fecal sample preparation. Additionally, the platform has automated analysis and does not require specialized staff training. Assuming development work is successfully completed Zomedica expects the commercial launch of the ZM-020 fecal test to occur by 2022 and urine tests by 2023. Zomedica is strategically committed to a singular commercial focus of its endocrine diagnostic platform, TRUFORMA™ through 2021.
Veterinarians only have access to slow, unreliable manual processes to identify fecal parasitic infections at the point-of-care. Consequently, veterinarians frequently send samples out to reference labs to test for and identify parasitic infections, which is relatively expensive and takes several days, delaying diagnosis and treatment. Zomedica’s ZM-020 is expected to deliver multiple benefits, including speed of results with minimal sample preparation time by leveraging the principles of Raman spectroscopy, machine learning, and patent pending design to achieve real-time analysis of a sample in a disposable cuvette. Zomedica believes that assay testing with ZM-020 can result in a definitive, reliable identification of fecal and urine infections within minutes. In addition to faster results and treatment, an added benefit to pet owners is expected to be the small sample size requirements, which are expected to reduce the burden of collection by the owner prior to the visit.
Zomedica’s exclusive development, commercialization and distribution agreement with Seraph gives Zomedica exclusive global veterinary industry rights to develop and market a pathogen detection system using Seraph’s technology to detect and identify pathogens at the point-of-care. The agreement includes pathogen detection in fecal, urine, skin matrices and respiratory samples. Because ZM-020 does not require pre-market regulatory approval for use with companion animals in the United States, Zomedica believes that it presents an attractive opportunity in terms of time to market and early revenue opportunities when compared to other diagnostic modalities.
“We are pleased that we have proven the ability to positively identify of all our targeted fecal and urine pathogens.” said Dr. Stephanie Morley, DVM, Zomedica’s President. “We believe that ZM-020 has the potential to make the diagnosis of fecal and urinary pathogen infection in cats and dogs easier, faster and more accurate than is currently possible at the point-of-care.”
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
About Seraph Biosciences
Incorporated in 2016, Seraph Biosciences is a healthcare technology company dedicated to commercializing Seraspec® – a fully-automated pathogen identification platform capable of delivering near real-time pathogen detection. Based in Detroit, Michigan, Seraph’s mission is to provide disruptive biomedical solutions to front-line providers and their patients at the point-of-care. For more information, visit https://www.seraspec.com/
Email Alerts: http://investors.zomedica.com
Except for statements of historical fact, this news release contains certain “forward-looking statements” or "forward-looking information" (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: market and other conditions, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and pilot and pivotal studies, uncertainty as to the likelihood and timing of regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services and achieve commercialization of products, such as fecal and urine detection using the ZM-020 platform; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, and intellectual property infringement risks; risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product; risks related to intellectual property protection, including the ability to obtain U.S. patents for our fecal and urine testing using the ZM-020 platform; and risks related to veterinary acceptance of our products, including the ZM-020 testing platform. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Shameze Rampertab, CPA, CA, Interim Chief Executive Officer
PCG Advisory Group
Kirin Smith, COO
+1 734.369.2555 ext. 119